Theravance Biopharma, Inc. - TBPH Enterprise Value-to-Revenue Multiple

Official company branding of theravance.com (TBPH)

Theravance Biopharma (TBPH) EV/Sales dynamics demonstrate moderate pressure due to uncertainty surrounding ampreloxetine trials and reliance on legacy royalties, with the 5439.46 value capturing this metric. Management is focused on developing safe therapies for respiratory and gastrointestinal diseases. Simultaneously, the company is implementing ESG standards through inventory control and the minimization of chemical waste to improve healthcare accessibility.

Theravance - TBPH EV/Sales Multiple (period 11/23/2025 - 10/10/2026)

Theravance Biopharma Inc - analytical breakdowns and key metrics (TBPH)

- cash balance and cash flow data:
Initial company analysis:Theravance Biopharma, TBPH
Flagship merchandise of Theravance Biopharma, Inc.

For Theravance Biopharma (TBPH), revenue-based valuation is critical due to its reliance on GSK royalties for Trelegy Ellipta. The company's EV/Sales multiple compares the total enterprise value, including debt minus cash, against annual turnover. This chart allows investors to filter out market noise and identify the actual overvaluation of the asset. An increase in this indicator reflects expectations for the R&D pipeline, while excessively high values signal a risk of capital correction.

Competitor analysis for Theravance Biopharma

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|Company Value to Revenue AQST (Aquestive Pharma)|SCPH - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to Revenue|China SXT Pharmaceuticals, Inc. - EV/Sales Multiple|EPRX - EV/Sales Multiple|BHST: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio